Creso clinches commercialisation deal for cannaQIX® UK launch
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Creso Pharma (ASX:CPH) has revealed it has penned a commercialisation agreement with Precision Healthcare to launch cannaQIX®10 and 50 in the UK. The launch is planned for the first quarter of the year.
Precision Healthcare is a UK-based privately held healthcare company which specialises in developing consumer healthcare products. It is part of Precision Marketing Group, a leading service provider to international pharmaceutical and healthcare companies. The company sells and distributes consumer healthcare brands to mass retailers and independent pharmacies covering more than 5000 points of sale in the UK.
CannaQIX® is CPH’s unique, proprietary formulated, nutraceutical product range containing full plant organic hemp extract with cannabidiol (CBD), vitamins and zinc. It aims to reduce stress and to support mental and nervous functions in humans.
The agreement covers the non-exclusive marketing and distribution of cannaQIX®10 and 50 in the UK market, targeting pharmacies and health food stores. This deal follows on from CPH’s receipt of confirmation for cannaQIX® as a food supplement from the UK Trading Standard Office (TSO).
Swiss regulatory authorities have issued a certificate of free sales for the export of the product into the UK from Switzerland.
While CPH has announced several positive developments, it should be noted here that it is in its early stages and investors should seek professional financial advice if considering this stock for their portfolio.
CPH CEO and co-founder, Dr Miri Halperin Wernli said: “We are delighted to partner with Precision Healthcare and to have obtained the necessary regulatory approvals for cannaQIX® in the UK – both significant milestones for our company.”
Precision Marketing Group CEO, Matthew Caldwell-Nichols added: “We are very pleased to work with Creso Pharma, who are a leading Swiss-based cannabis and hemp healthcare company, to market their innovative cannabis and hemp-based products, and we are looking forward to a successful business partnership.”
The cannaQIX® range
The cannaQIX® products are hemp-based nutraceuticals which utilise CPH’s proprietary innovative delivery technology.
The proprietary QIX-technology based delivery system contains capsicum, which accelerates blood circulation in the mouth, enhancing the buccal, sublingual delivery of the CBD, vitamins and zinc into the bloodstream.
The product is safe, well tolerated, non-euphoric, non-addictive and sugar-free. The standardised, user-friendly strength and formulation allows precise dosage control, ensuring a reliable and stable effect over several days.
The cannaQIX® range has been developed to Good Manufacturing Practice (GMP) standards and is produced in Switzerland by CPH’s partner, Swiss-based food and pharma development company, DOMACO Dr. med Aufdermaur AG (Domaco), to the highest Swiss quality and with a “Swiss Made” label.
With this product range, CPH is offering consumers a safe and effective certified food supplement with CBD, with broad market reach and without the need for medical prescriptions.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.